Tag: Bristol-Myers Squibb

Pharmaceutical giant Bristol-Myers Squibb finds itself navigating contrasting currents as recent European regulatory approvals clash with a significant clinical trial ...

Investors in Bristol-Myers Squibb encountered a significant market downturn as the pharmaceutical giant and its collaborator, Johnson & Johnson, terminated ...

The pharmaceutical giant's intensified focus on cancer research is yielding tangible results. Bristol-Myers Squibb is advancing its oncology pipeline through ...

After an extended period of decline, Bristol-Myers Squibb shares are showing signs of a potential turnaround. A combination of robust ...

Pharmaceutical giant Bristol-Myers Squibb finds itself managing multiple complex situations simultaneously. While the company recently demonstrated robust quarterly results and ...

Pharmaceutical giant Bristol-Myers Squibb finds itself navigating complex challenges as its stock continues to face downward pressure despite demonstrating operational ...

Pharmaceutical giant Bristol-Myers Squibb has demonstrated a remarkable turnaround, with its latest quarterly report exceeding investor expectations through unexpectedly robust ...

Pharmaceutical giant Bristol-Myers Squibb faces a critical transition period as it races to offset substantial revenue declines expected from key ...

Pharmaceutical giant Bristol-Myers Squibb is making a substantial $1.5 billion strategic move to acquire biotechnology firm Orbital Therapeutics, signaling a ...

Bristol-Myers Squibb has secured a significant regulatory milestone for its Alzheimer's drug candidate BMS-986446, receiving Fast Track designation from the ...